"In 2002, Professor Holyoake was the first to demonstrate that CML stem cells are completely insensitive to killing by first generation kinase inhibitor, imatinib. These findings published in Blood highlighted that kinase inhibitors alone would be unlikely to cure CML."
A recent study, led by Prof Holyoake analysed both CML and normal blood stem cells and found two proteins that were key to the survival of CML stem cells. The group then developed a drug combination to simultaneously target these critical proteins and kill the CML stem cells, while largely sparing normal cells. This research, published in Nature, although at an early stage, is a fantastic example of precision medicine in action."
Extract of "Prof Tessa Holyoake recognised for ground-breaking research into CML"
Learn more about Professor Tessa L Holyoake ------- See the videos